Cantor Fitzgerald Weighs in on Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Kura Oncology in a research report issued to clients and investors on Wednesday, March 19th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($2.21) per share for the year, up from their prior estimate of ($2.94). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million.

A number of other brokerages also recently issued reports on KURA. UBS Group decreased their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Scotiabank decreased their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Trading Down 0.1 %

Shares of KURA stock opened at $7.84 on Friday. Kura Oncology has a fifty-two week low of $6.79 and a fifty-two week high of $23.48. The company has a 50 day moving average price of $7.82 and a 200 day moving average price of $12.43. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market capitalization of $633.12 million, a P/E ratio of -3.32 and a beta of 0.85.

Insider Activity at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 in the last 90 days. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Kura Oncology by 7.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock valued at $1,147,000 after buying an additional 9,050 shares during the period. Woodline Partners LP increased its stake in Kura Oncology by 20.6% in the 4th quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock valued at $1,504,000 after buying an additional 29,497 shares during the period. Velan Capital Investment Management LP acquired a new position in Kura Oncology in the 4th quarter valued at $1,306,000. Squarepoint Ops LLC acquired a new position in Kura Oncology in the 4th quarter valued at $799,000. Finally, Two Sigma Advisers LP increased its stake in Kura Oncology by 147.1% in the 4th quarter. Two Sigma Advisers LP now owns 242,200 shares of the company’s stock valued at $2,110,000 after buying an additional 144,201 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.